Redeye provides an update following Litium’s acquisition of Geins, a small but strategically sound deal that brings both technical capabilities and a customer base of some 25 clients. The transaction adds ~11% to ARR and the 6% rights issue discount and broad insider participation reflect strong backing. We lift our estimates slightly across the board.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/